APA-referens (7:e uppl.)

Hermine, O., Mariette, X., Porcher, R., Djossou, F., Nguyen, Y., Arlet, J., . . . Ravaud, P. (2022). Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia. EClinicalMedicine, 46(101362-), . https://doi.org/10.1016/j.eclinm.2022.101362

Chicago-referens (17:e uppl.)

Hermine, Olivier, et al. "Tocilizumab Plus Dexamethasone Versus Dexamethasone in Patients with Moderate-to-severe COVID-19 Pneumonia." EClinicalMedicine 46, no. 101362- (2022). https://doi.org/10.1016/j.eclinm.2022.101362.

MLA-referens (9:e uppl.)

Hermine, Olivier, et al. "Tocilizumab Plus Dexamethasone Versus Dexamethasone in Patients with Moderate-to-severe COVID-19 Pneumonia." EClinicalMedicine, vol. 46, no. 101362-, 2022, https://doi.org/10.1016/j.eclinm.2022.101362.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.